CLINICAL CHARACTERISTICS AND RENAL RISK OF PATIENTS WITH CHRONIC KIDNEY DISEASE: REAL-WORLD EVIDENCE FROM THE ICAREME GLOBAL REGISTRY

被引:0
|
作者
Arici, Mustafa [1 ]
Pollock, Carol [2 ]
Goncalves, Susana [3 ]
Vasnawala, Hardik [4 ]
Hadaoui, Ahmed [5 ]
机构
[1] Hacettepe Univ, Fac Med, Dept Nephrol, Ankara, Turkiye
[2] Univ Sydney, Royal North Shore Hosp, Kolling Inst, Camperdown, NSW, Australia
[3] AstraZeneca Int, Med Affairs, Buenos Aires, Argentina
[4] AstraZeneca Int, Med Affairs, Bengaluru, India
[5] AstraZeneca Algeria, Med Affairs, Buenos Aires, Argentina
关键词
D O I
暂无
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
6054
引用
收藏
页码:I544 / I545
页数:2
相关论文
共 50 条
  • [21] Characteristics of patients treated for CLL in a real-world registry: results from informCLL™
    Mato, Anthony
    Sharman, Jeff
    Pagel, John
    Brander, Danielle
    Kadish, Karen
    Tomlinson, Brian
    Ipe, David
    Yang, Huiying
    Arango-Hisijara, Israel
    Srivastava, Bhavini
    Schenkel, Brad
    Barrientos, Jacqueline
    LEUKEMIA & LYMPHOMA, 2017, 58 : 48 - 49
  • [22] REAL-WORLD EVIDENCE, CLINICAL CHARACTERISTICS, & DISEASE PROGRESSION INSIGHTS FROM A GLOBAL COHORT OF PRIMARY BILIARY CHOLANGITIS PATIENTS DIAGNOSED BETWEEN 2015 AND 2023
    Amato, Gianni
    Thompson, Courtney
    HEPATOLOGY, 2023, 78 : S2069 - S2069
  • [23] REAL WORLD EVIDENCE OF THE RISK OF STROKE OR SYSTEMIC EMBOLISM IN CHRONIC KIDNEY DISEASE PATIENTS WITH ATRIAL FIBRILLATION
    Kuranz, S.
    VALUE IN HEALTH, 2018, 21 : S97 - S97
  • [24] AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps
    Siddiqui, Shahid
    Bachert, Claus
    Chaker, Adam M.
    Han, Joseph K.
    Hellings, Peter W.
    Peters, Anju T.
    Heffler, Enrico
    Kamat, Siddhesh
    Zhang, Haixin
    Nash, Scott
    Khan, Asif H.
    Gomez, Lucia De Prado
    Jacob-Nara, Juby A.
    Rowe, Paul J.
    Deniz, Yamo
    ERJ OPEN RESEARCH, 2022, 8 (04)
  • [25] Real-World Evidence from the OPUS Registry: An Insight into Pulmonary Arterial Hypertension Risk Assessment Parameters in Clinical Practice
    Chin, K. M.
    Channick, R. N.
    Kim, N. H.
    Brand, M.
    Morganti, A.
    Selej, M.
    McLaughlin, V. V.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [26] Chronic Kidney Disease Testing Among At-Risk Adults in the US Remains Low: Real-World Evidence From a National Laboratory Database
    Alfego, David
    Ennis, Jennifer
    Gillespie, Barbara
    Lewis, Mary Jane
    Montgomery, Elizabeth
    Ferre, Silvia
    Vassalotti, Joseph A.
    Letovsky, Stanley
    DIABETES CARE, 2021, 44 (09) : 2025 - 2032
  • [27] Adherence of Elderly Patients with Cardiovascular Disease to Statins and the Risk of Exacerbation of Chronic Obstructive Pulmonary Disease: Evidence from an Italian Real-World Investigation
    Federico Rea
    Giulia Calusi
    Matteo Franchi
    Davide Liborio Vetrano
    Giuseppe Roberto
    Stefano Bonassi
    Ursula Kirchmayer
    Alessandro Chinellato
    Alessandra Bettiol
    Janet Sultana
    Alessandro Mugelli
    Giovanni Corrao
    Drugs & Aging, 2018, 35 : 1099 - 1108
  • [28] Adherence of Elderly Patients with Cardiovascular Disease to Statins and the Risk of Exacerbation of Chronic Obstructive Pulmonary Disease: Evidence from an Italian Real-World Investigation
    Rea, Federico
    Calusi, Giulia
    Franchi, Matteo
    Vetrano, Davide Liborio
    Roberto, Giuseppe
    Bonassi, Stefano
    Kirchmayer, Ursula
    Chinellato, Alessandro
    Bettiol, Alessandra
    Sultana, Janet
    Mugelli, Alessandro
    Corrao, Giovanni
    DRUGS & AGING, 2018, 35 (12) : 1099 - 1108
  • [29] The Effect of Renal Impairment on Outcomes from the Real-World EFive Registry
    Rothman, Martin T.
    Meredith, Ian T.
    Sinha, Nakul
    Chandra, Praveen
    Herrera, Antonio Merchan
    Lotan, Chaim
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (10) : A83 - A83
  • [30] The Seriousness of Chronic Venous Disease: A Review of Real-World Evidence
    Davies, Alun H.
    ADVANCES IN THERAPY, 2019, 36 (Suppl 1) : 5 - 12